Sign in
← Database
Melanocortin Agonist

Bremelanotide

Buy · Omnichems ↗Buy · Disguised Alpha ↗
Third-party suppliers · research use only · not an endorsement. Some links are affiliate links — purchases made through them may earn this site a commission.
Overview

FDA-approved (Vyleesi) for premenopausal HSDD, supported by randomized trials.

How it works

Bremelanotide (PT-141) works on the melanocortin system in the brain rather than on blood vessels. It activates melanocortin receptors — chiefly MC4R — in regions that govern sexual motivation.

This is fundamentally different from erectile-dysfunction drugs like sildenafil, which act on peripheral blood flow. Bremelanotide's effect is central: by switching on these brain circuits it increases sexual desire and arousal, which is why it's approved for hypoactive sexual desire disorder in premenopausal women.

It's a short-acting injection used as needed. Because it activates melanocortin receptors broadly (not just MC4R), it can cause a transient rise in blood pressure along with nausea and flushing.

Mechanism · Detailed Analysis
Molecular targetNon-selective melanocortin-receptor agonist acting primarily via central MC4R (with MC1R activity).
Signaling & downstream effectsMC4R activation in hypothalamic and limbic circuits increases sexual desire and arousal — a central mechanism distinct from the peripheral vasodilation of PDE5 inhibitors.
PharmacokineticsShort-acting; dosed subcutaneously on an as-needed basis.
CaveatsBroad melanocortin activity produces transient blood-pressure rise, nausea, and flushing.
Published EvidenceLoading cited studies from PubMed…
Human Data ···

Searching the published record…

Animal ···

Searching the published record…

In Vitro ···

Searching the published record…

Educational aggregation of public literature. Not medical advice and not a recommendation to use any compound. Many compounds here are not approved for human use. Consult a licensed clinician.